A comparative study of two laser techniques for tattoo removal.

A split tattoo comparative evaluation of sequential QS nanosecond laser followed by QS picosecond laser versus QS picosecond laser alone in tattoo removal: a prospective study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/096766

Enrollment

Registered

2025-11-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L818- Other specified disorders of pigmentation

Interventions

Intervention1: Q-switched nanosecond laser: On Split Half A, Q-switched nanosecond laser at 532/650/1064 nm (5–10 ns pulse duration) will be applied with a spot size of 3–6 mm, repetition rate of 1–5

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adults 18 to 70 years willing to consent. 2.One or more stable tattoos (professional or amateur), greater than or equal to 3 months old. 3.Tattoo containing single or multi-colour ink. 4.Agree not to undergo any other tattoo removal procedure during the treatment duration.

Exclusion criteria

Exclusion criteria: 1.Associated photo-aggravated skin diseases and medical illnesses, for example, SLE. 2.Treatment area with active cutaneous infection or inflammation. 3.Unstable vitiligo and psoriasis 4.Tattoo granuloma 5.Localised allergic reactions within a tattoo 6.Recent sun exposure in the past 3 weeks 7.Immunosuppression or uncontrolled systemic disease 8.History of keloid and keloidal tendency 9.Personal or family history of skin cancer 10.Photosensitising or gold-containing medication 11.Pregnancy or lactation 12.Seizure disorder 13.Patient not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
Efficacy of tattoo removal: Assessed as the percentage of tattoo clearance using Physician Global Assessment (PGA) scale at baseline and after 4 treatment sessions (week 16)Timepoint: After 4 months	—

Secondary

Measure	Time frame
The study will assess the efficacy of tattoo removal as the percentage of clearance using the Physician Global Assessment (PGA) scale at baseline and after 4 treatment sessions (week 16). Pain during treatment will be recorded using the Visual Analogue Scale (VAS 0–10) at each session, patient satisfaction will be evaluated on a Likert scale (1–5) after completion of all sessions, and any adverse effects will be documented and graded according to severity.Timepoint: After 4 months	—

Measure

Time frame

The study will assess the efficacy of tattoo removal as the percentage of clearance using the Physician Global Assessment (PGA) scale at baseline and after 4 treatment sessions (week 16). Pain during treatment will be recorded using the Visual Analogue Scale (VAS 0–10) at each session, patient satisfaction will be evaluated on a Likert scale (1–5) after completion of all sessions, and any adverse effects will be documented and graded according to severity.Timepoint: After 4 months

—

Countries

India

Contacts

Public ContactDr Chaithra Shenoy

CUTIS Academy of Cutaneous Sciences

chaithrashenoy@gmail.com9739247155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026